Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))

BACKGROUND AND OBJECTIVES: Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody (mAb) that binds to the HER2 protein. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States (trastuzumab-US) and European Union (trastuzumab-EU). Nonclini...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hurst, Susan, Ryan, Anne M., Ng, Chee-Keng, McNally, James M., Lorello, Leslie G., Finch, Gregory L., Leach, Michael W., Ploch, Stephen A., Fohey, Josh A., Smolarek, Teresa A.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2014
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176567/
https://ncbi.nlm.nih.gov/pubmed/25001079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-014-0103-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars